Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3345211 | 0.98 | HRH3 (0.46) | HRH3 | |
| SCHEMBL3347181 | 0.96 | HRH3 (0.40) | HRH3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3315257 | 0.84 | HRH3 (0.35) | HRH3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL18389972 | 0.84 | HTR1A (0.53) | HRH3 | |
| SCHEMBL9760411 | 0.83 | HRH3 (0.44) | HRH3 | |
| SCHEMBL3347099 | 0.82 | CA2 (0.39) | HRH3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3317327 | 0.82 | HRH3 (0.38) | HRH3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL26725202 | 0.82 | HRH3 (0.46) | HRH3 | |
| SCHEMBL18389978 | 0.81 | HRH3 (0.50) | HRH3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL15904342 | 0.81 | HRH3 (0.41) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2025-02-20 | — | — | US | disclosed |
| US-20220267318-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2022-08-25 | — | — | US | disclosed |
| US-5041454-A | Stimulate gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-08-20 | — | — | US | disclosed |
| US-4975439-A | Gastrointestinal motility stimulating properties | JANSSEN PHARMACEUTICAL N.V. (BE) | 1990-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267318-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | HRH3 1525/4885CHRNB2 2797/4885CHRNB4 3141/4885 |
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | HRH3 1525/4885CHRNB2 2797/4885CHRNB4 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.